| DTx Pharma Raises $10.6M to Advance New Way to Deliver RNA Drugs | Sarah de Crescenzo | 01/09/20 | San Diego |
| Solid Bio Restructures to Get Halted Gene Therapy Study Back on Track | Frank Vinluan | 01/09/20 | Boston |
| UK Startups Double in Number Backed By Larger Scale Investments: Report | Melissa Fassbender | 01/09/20 | National |
| Empirico Raises $17M, Inks 3-Year Antisense Collaboration with Ionis | Sarah de Crescenzo | 01/09/20 | San Diego |
| Novome Lands $33M to Tweak a Gut Microbe Into a Metabolic Therapy | Frank Vinluan | 01/08/20 | San Francisco |
| Mirati Adds Execs With Commercial Experience at Spark, Bristol-Myers | Sarah de Crescenzo | 01/08/20 | San Diego |
| Novo Holdings Repositions Antibiotics Funding Amid “Deteriorated” Market | Melissa Fassbender | 01/07/20 | National |
| Apellis Rare Blood Disease Drug Tops Alexion’s in Head-to-Head Test | Frank Vinluan | 01/07/20 | Boston |
| Takeda to Fund AI Projects at MIT as Part of New 3-Year Collaboration | Melissa Fassbender | 01/07/20 | Boston |
| Celgene-Seeded PharmAkea Sells Last Fibrotic Drug Candidate to Galecto | Sarah de Crescenzo | 01/07/20 | San Diego |
| Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic | Frank Vinluan | 01/07/20 | Boston |
| BioIntervene Raises $30M to Move Nerve Pain Drug Into the Clinic | Sarah de Crescenzo | 01/07/20 | San Diego |
| Merck Ramps Up KRAS Chase Through Licensing Deal With Taiho, Astex | Frank Vinluan | 01/06/20 | New York |
| China’s CF PharmTech Raises $90M to Advance Respiratory Drug Development | Melissa Fassbender | 01/06/20 | National |
| Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More | Frank Vinluan | 01/03/20 | National |
| After Antitrust Challenges, Illumina and PacBio Throw in Towel on Merger | Sarah de Crescenzo | 01/03/20 | San Diego |
| No More Fish or Fruit: Intrexon Turns SynBio Focus to Human Health | Frank Vinluan | 01/02/20 | National |
| Rexgenero CEO Talks Importance of “Dialogue” in Cell Therapy Conversations | Sarah de Crescenzo | 01/02/20 | National |
| Wave’s Huntington’s Drug Disappoints in Clinical Trial, Stock Sinks | Melissa Fassbender | 01/02/20 | Boulder/Denver |
| Investors Go With Gut Ahead of Microbiome Therapy Boom, Says Seventure | Dan Stanton | 01/01/20 | National |
| Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines | Sarah de Crescenzo | 12/24/19 | National |
| Evotec CEO Discusses Ways to Make Drug R&D Faster and Better | Melissa Fassbender | 12/24/19 | National |
| Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal | Sarah de Crescenzo | 12/23/19 | Boston |
| Healthcare AI Tech is Here, Now We Must Learn to Manage the Data | Dan Stanton | 12/23/19 | National |
| Bio Roundup: Amarin’s Approval, FTC v. Illumina, a $120M Deal & More | Sarah de Crescenzo | 12/20/19 | National |
| Biogen Strikes Alzheimer’s Deal, Paying $45M for Ionis Tau Drug Rights | Sarah de Crescenzo | 12/19/19 | San Diego |
| Takeda Pays Turnstone $120M to Start Alliance on Viral Cancer Therapies | Frank Vinluan | 12/19/19 | New York |
| Ring Therapeutics Launches to Expand Gene Therapy Viral Vector Options | Sarah de Crescenzo | 12/19/19 | Boston |
| ArcherDX Raises $55M to Help Physicians Pick Best Cancer Therapies | Melissa Fassbender | 12/18/19 | Boulder/Denver |
| FTC Challenges PacBio Acquisition, Says Illumina is a “Monopolist” | Sarah de Crescenzo | 12/18/19 | San Diego |
